Living Cell Technologies Ltd (LVCLF) 0.0380 $LVCLF
Living Cell Technologies' NTCELL(R) Demonstrates Continued Reversal of Parkinson's Disease
BusinessWire - Tue Jun 07, 1:13AM CDT
81 weeks after treatment all four patients who took part in Living Cell Technologies Limited's Phase I/IIa clinical study of NTCELL(R) for Parkinson's disease show reversal of the progression of Parkinson's disease as measured by globally accepted and validated Unified Parkinson's Disease Rating Scale (UPDRS).
LCT Starts Phase IIb Clinical Trial of NTCELL for Parkinson's Disease
BusinessWire - Wed Mar 23, 7:16PM CDT
Living Cell Technologies has received approval from the Auckland Hospital Research Review Committee for the Phase IIb clinical trial of NTCELL(R) for Parkinson's disease. The New Zealand Minister of Health authorised the application to conduct the trial on 12 November 2015, and the Northern A Health and Disability Ethics Committee gave its approval on 3 February 2016. The initiation meeting with all those involved in the clinical trial has been held and patient recruitment is under way.
Huntington's Disease Pipeline Review, H2 2015
M2 - Thu Jan 21, 9:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/kbmbtc/huntingtons) has announced the addition of the "Huntington's Disease - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Huntington's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Huntington's Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Huntington's Disease Overview - Therapeutics Development - Pipeline Products for Huntington's Disease - Overview - Pipeline Products for Huntington's Disease - Comparative Analysis - Huntington's Disease - Therapeutics under Development by Companies - Huntington's Disease - Therapeutics under Investigation by Universities/Institutes - Huntington's Disease - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Huntington's Disease - Products under Development by Companies - Huntington's Disease - Products under Investigation by Universities/Institutes - Huntington's Disease - Companies Involved in Therapeutics Development - Addex Therapeutics Ltd - AFFiRiS AG - Alnylam Pharmaceuticals, Inc. - Angita B.V. - Astellas Pharma Inc. - Azevan Pharmaceuticals, Inc. - BioCrea GmbH - BioMarin Pharmaceutical Inc. - BrainStorm Cell Therapeutics Inc. - Chong Kun Dang Pharmaceutical Corp. - Kadmon Corporation, LLC - KineMed, Inc. - Living Cell Technologies Limited - Medesis Pharma S.A. - Neuralstem, Inc. - Neurimmune Holding AG - NeuroNascent, Inc. - New World Laboratories, Inc. - nLife Therapeutics, S.L. - NsGene A/S - Provid Pharmaceuticals, Inc. - QR Pharma, Inc. - Raptor Pharmaceuticals Inc - reMYND NV - RestorGenex Corporation - Rhenovia Pharma Limited - Sangamo BioSciences, Inc. - Vaccinex, Inc. - Vertex Pharmaceuticals Incorporated - VistaGen Therapeutics , Inc. - VivaCell Biotechnology Espana S.L. - Voyager Therapeutics, Inc. - Vybion, Inc. - Zenobia Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/kb...untingtons
VRTX: 85.22 (-0.06), BMRN: 82.18 (+0.96), VYGR: 12.24 (-0.90), RPTP: 5.13 (+0.04), KNMD: (), SGMO: 5.62 (-0.02), BCLI: 2.44 (+0.05), CUR: 0.30 (-0.02)
Huntington's Disease - Pipeline Review, H1 2015
M2 - Thu Sep 03, 5:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q79g5p/huntingtons) has announced the addition of the "Huntington's Disease - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Huntington's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Huntington's Disease and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned - Acadia Pharmaceuticals - Addex Therapeutics - BioCrea - BioMarin Pharmaceutical - Cortex Pharmaceuticals - CrystalGenomics - EncephRx - Evotec - F. Hoffmann-La Roche - Galenea - Genervon Biopharmaceuticals - Ipsen - Isis Pharmaceuticals - Kadmon Corporation - KineMed - Living Cell Technologies - Marathon Pharmaceuticals - Medesis Pharma - Neuralstem - Neurimmune - Omeros - Oryzon Genomics - Pfizer - PharmatrophiX - Raptor Pharmaceuticals - reMYND - Sangamo BioSciences - Siena Biotech - Teva Pharmaceutical Industries - Treventis - Ultragenyx Pharmaceutical - uniQure - Vaccinex - Varine - Zenobia Therapeutics For more information visit http://www.researchandmarkets.com/research/q7...untingtons
ACAD: 33.50 (-1.49), BMRN: 82.18 (+0.96), RPTP: 5.13 (+0.04), ISIS: 57.56 (-0.28), SGMO: 5.62 (-0.02), TEVA: 51.19 (+0.21)
Wounds - Pipeline Review, H1 2015 - Reviews Key Players Involved in the Therapeutics Development for Wounds
M2 - Mon Aug 17, 6:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wfxjz3/wounds_pipeline) has announced the addition of the "Wounds - Pipeline Review, H1 2015" report to their offering. Summary This, Wounds - Pipeline Review, H1 2015', provides an overview of the Wounds's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Wounds, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wounds and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Scope - The report provides a snapshot of the global therapeutic landscape of Wounds - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report summarizes all the dormant and discontinued pipeline projects - A review of the Wounds products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned - Advancell - Aerpio Therapeutics, Inc. - Agenta Biotechnologies, Inc. - AlgiPharma AS - AndroScience Corporation - AnGes MG, Inc. - APEIRON Biologics AG - Aridis Pharmaceuticals LLC - Beech Tree Labs, Inc. - Bio3 Research S.r.l - Biokine Therapeutics Ltd. - Biotec Pharmacon ASA - Birken AG - Blueberry Therapeutics Ltd - Caladrius Biosciences, Inc. - Cellphire, Inc. - CorMedix, Inc. - CYATHUS EXQUIRERE PharmaforschungsGmbH - Destiny Pharma Limited - FibroGen, Inc. - Foresee Pharmaceuticals, LLC - GangaGen Inc. - Garnet BioTherapeutics - Gene Signal International SA - GlaxoSmithKline Plc - HanAll Biopharma Co., Ltd. - IntelliCell BioSciences Inc. - Juventas Therapeutics, Inc. - Kasiak Research Pvt. Ltd. - Kuros Biosurgery AG - LegoChem Biosciences, Inc - Living Cell Technologies Limited - MediWound Ltd. For more information visit http://www.researchandmarkets.com/research/wf...s_pipeline
CRMD: 2.08 (-0.07), MDWD: 7.97 (-0.08), FGEN: 15.50 (-0.18), GSK: 41.76 (+0.11), CLBS: 0.51 (+0.02)
NTCELL(R) Clinical Study in Parkinson's Meets Endpoints
BusinessWire - Sun Jun 14, 7:40PM CDT
--Company to Host Conference Call on Wednesday, June 17, at 3:30 p.m. Pacific Daylight Time
Hearing Disorders - Pipeline Review, H2 2014
M2 - Wed Dec 10, 4:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/skj5jn/hearing_disorders) has announced the addition of the "Hearing Disorders - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hearing Disorders, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hearing Disorders and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hearing Disorders - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hearing Disorders pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Affichem - AudioCure Pharma GmbH - Edison Pharmaceuticals, Inc. - Fate Therapeutics, Inc. - Living Cell Technologies Limited - Novartis AG - Otologic Pharmaceutics, Inc. - Pharmicell Co., Ltd. - Quark Pharmaceuticals, Inc. - Sound Pharmaceuticals, Inc. - uniQure NV For more information visit http://www.researchandmarkets.com/research/sk..._disorders
FATE: 1.83 (-0.06), NVS: 79.71 (+0.25)
Living Cell Technologies' NTCELL(R) Demonstrates Continued Reversal of Parkinson's Disease
BusinessWire - Tue Jun 07, 1:13AM CDT
81 weeks after treatment all four patients who took part in Living Cell Technologies Limited's Phase I/IIa clinical study of NTCELL(R) for Parkinson's disease show reversal of the progression of Parkinson's disease as measured by globally accepted and validated Unified Parkinson's Disease Rating Scale (UPDRS).
LCT Starts Phase IIb Clinical Trial of NTCELL for Parkinson's Disease
BusinessWire - Wed Mar 23, 7:16PM CDT
Living Cell Technologies has received approval from the Auckland Hospital Research Review Committee for the Phase IIb clinical trial of NTCELL(R) for Parkinson's disease. The New Zealand Minister of Health authorised the application to conduct the trial on 12 November 2015, and the Northern A Health and Disability Ethics Committee gave its approval on 3 February 2016. The initiation meeting with all those involved in the clinical trial has been held and patient recruitment is under way.
Huntington's Disease Pipeline Review, H2 2015
M2 - Thu Jan 21, 9:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/kbmbtc/huntingtons) has announced the addition of the "Huntington's Disease - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Huntington's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Huntington's Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Huntington's Disease Overview - Therapeutics Development - Pipeline Products for Huntington's Disease - Overview - Pipeline Products for Huntington's Disease - Comparative Analysis - Huntington's Disease - Therapeutics under Development by Companies - Huntington's Disease - Therapeutics under Investigation by Universities/Institutes - Huntington's Disease - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Huntington's Disease - Products under Development by Companies - Huntington's Disease - Products under Investigation by Universities/Institutes - Huntington's Disease - Companies Involved in Therapeutics Development - Addex Therapeutics Ltd - AFFiRiS AG - Alnylam Pharmaceuticals, Inc. - Angita B.V. - Astellas Pharma Inc. - Azevan Pharmaceuticals, Inc. - BioCrea GmbH - BioMarin Pharmaceutical Inc. - BrainStorm Cell Therapeutics Inc. - Chong Kun Dang Pharmaceutical Corp. - Kadmon Corporation, LLC - KineMed, Inc. - Living Cell Technologies Limited - Medesis Pharma S.A. - Neuralstem, Inc. - Neurimmune Holding AG - NeuroNascent, Inc. - New World Laboratories, Inc. - nLife Therapeutics, S.L. - NsGene A/S - Provid Pharmaceuticals, Inc. - QR Pharma, Inc. - Raptor Pharmaceuticals Inc - reMYND NV - RestorGenex Corporation - Rhenovia Pharma Limited - Sangamo BioSciences, Inc. - Vaccinex, Inc. - Vertex Pharmaceuticals Incorporated - VistaGen Therapeutics , Inc. - VivaCell Biotechnology Espana S.L. - Voyager Therapeutics, Inc. - Vybion, Inc. - Zenobia Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/kb...untingtons
VRTX: 85.22 (-0.06), BMRN: 82.18 (+0.96), VYGR: 12.24 (-0.90), RPTP: 5.13 (+0.04), KNMD: (), SGMO: 5.62 (-0.02), BCLI: 2.44 (+0.05), CUR: 0.30 (-0.02)
Huntington's Disease - Pipeline Review, H1 2015
M2 - Thu Sep 03, 5:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q79g5p/huntingtons) has announced the addition of the "Huntington's Disease - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Huntington's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Huntington's Disease and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned - Acadia Pharmaceuticals - Addex Therapeutics - BioCrea - BioMarin Pharmaceutical - Cortex Pharmaceuticals - CrystalGenomics - EncephRx - Evotec - F. Hoffmann-La Roche - Galenea - Genervon Biopharmaceuticals - Ipsen - Isis Pharmaceuticals - Kadmon Corporation - KineMed - Living Cell Technologies - Marathon Pharmaceuticals - Medesis Pharma - Neuralstem - Neurimmune - Omeros - Oryzon Genomics - Pfizer - PharmatrophiX - Raptor Pharmaceuticals - reMYND - Sangamo BioSciences - Siena Biotech - Teva Pharmaceutical Industries - Treventis - Ultragenyx Pharmaceutical - uniQure - Vaccinex - Varine - Zenobia Therapeutics For more information visit http://www.researchandmarkets.com/research/q7...untingtons
ACAD: 33.50 (-1.49), BMRN: 82.18 (+0.96), RPTP: 5.13 (+0.04), ISIS: 57.56 (-0.28), SGMO: 5.62 (-0.02), TEVA: 51.19 (+0.21)
Wounds - Pipeline Review, H1 2015 - Reviews Key Players Involved in the Therapeutics Development for Wounds
M2 - Mon Aug 17, 6:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wfxjz3/wounds_pipeline) has announced the addition of the "Wounds - Pipeline Review, H1 2015" report to their offering. Summary This, Wounds - Pipeline Review, H1 2015', provides an overview of the Wounds's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Wounds, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wounds and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Scope - The report provides a snapshot of the global therapeutic landscape of Wounds - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report summarizes all the dormant and discontinued pipeline projects - A review of the Wounds products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned - Advancell - Aerpio Therapeutics, Inc. - Agenta Biotechnologies, Inc. - AlgiPharma AS - AndroScience Corporation - AnGes MG, Inc. - APEIRON Biologics AG - Aridis Pharmaceuticals LLC - Beech Tree Labs, Inc. - Bio3 Research S.r.l - Biokine Therapeutics Ltd. - Biotec Pharmacon ASA - Birken AG - Blueberry Therapeutics Ltd - Caladrius Biosciences, Inc. - Cellphire, Inc. - CorMedix, Inc. - CYATHUS EXQUIRERE PharmaforschungsGmbH - Destiny Pharma Limited - FibroGen, Inc. - Foresee Pharmaceuticals, LLC - GangaGen Inc. - Garnet BioTherapeutics - Gene Signal International SA - GlaxoSmithKline Plc - HanAll Biopharma Co., Ltd. - IntelliCell BioSciences Inc. - Juventas Therapeutics, Inc. - Kasiak Research Pvt. Ltd. - Kuros Biosurgery AG - LegoChem Biosciences, Inc - Living Cell Technologies Limited - MediWound Ltd. For more information visit http://www.researchandmarkets.com/research/wf...s_pipeline
CRMD: 2.08 (-0.07), MDWD: 7.97 (-0.08), FGEN: 15.50 (-0.18), GSK: 41.76 (+0.11), CLBS: 0.51 (+0.02)
NTCELL(R) Clinical Study in Parkinson's Meets Endpoints
BusinessWire - Sun Jun 14, 7:40PM CDT
--Company to Host Conference Call on Wednesday, June 17, at 3:30 p.m. Pacific Daylight Time
Hearing Disorders - Pipeline Review, H2 2014
M2 - Wed Dec 10, 4:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/skj5jn/hearing_disorders) has announced the addition of the "Hearing Disorders - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hearing Disorders, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hearing Disorders and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hearing Disorders - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hearing Disorders pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Affichem - AudioCure Pharma GmbH - Edison Pharmaceuticals, Inc. - Fate Therapeutics, Inc. - Living Cell Technologies Limited - Novartis AG - Otologic Pharmaceutics, Inc. - Pharmicell Co., Ltd. - Quark Pharmaceuticals, Inc. - Sound Pharmaceuticals, Inc. - uniQure NV For more information visit http://www.researchandmarkets.com/research/sk..._disorders
FATE: 1.83 (-0.06), NVS: 79.71 (+0.25)
